Clinical observation of Kucai paste combined with Entecavir in the treatment of chronic hepatitis B liver fibrosis
Objective To explore the clinical effect of Kucai paste combined with Entecavir in the treatment of chronic hepatitis B liver fibrosis with stagnation of liver qi and spleen deficiency syndrome.Methods A total of 60 patients with chronic hepatitis B liver fibrosis with stagnation of liver qi and spleen deficiency syndrome admitted to Yulin Hospital of Traditional Chinese Medicine from January 2019 to December 2022 were divided into the control group and the observation group according to random number table method,with 30 cases in each group.The control group was given Entecavir capsules,and received 0.5mg orally each time,once a day.On the basis of the treatment of the control group,the observation group was given Kucai paste,and received 10g orally each time,twice a day.The treatment period of both groups was 48 weeks.Four serological liver fibrosis indexes[hyaluronic acid(HA),type Ⅳ collagen(Ⅳ-C),precollagen type Ⅲ(PC-Ⅲ),laminin(LN)]levels,liver function indexes(AST,TBil,ALT)levels,liver stiffness measurements(LSM),negative conversion rate of HBV DNA,negative conversion rate of HBeAg,and the efficacy of traditional Chinese medicine(TCM)syndromes were compared between the observation group and the control group before and after treatment.Results The levels of AST,ALT,TBil,PC-Ⅲ,LN,HA,Ⅳ-C,and LSM values in the observation group were significantly lower than those in the control group(P＜0.05).The negative conversion rate of HBV DNA in the observation group at 48 weeks was higher than that in the control group(P＜0.05).There was no statistically signigicant difference in the negative conversion rate of HBeAg in the observation group compared to the control group(P＞0.05).The TCM symptom score in the observation group was significantly lower than that in the control group(P＜0.05).The total effective rate in the observation group was significantly higher than that in the control group(P＜0.05).Conclusion After treatment with Kucai paste combined with Entecavir,the clinical symptoms and liver function of patients with chronic hepatitis B liver fibrosis are significantly improved,and serological liver fibrosis indexes levels and LSM are all reduced,which improves the clinical efficacy.
Kucai pasteEntecavirchronic hepatitis Bhepatic fibrosissyndrome of stagnation of liver qi and spleen deficiency
万方数据
维普
